TSH Level and Risk of Malignancy in Patients with Bethesda Category IV Thyroid Nodules
- 8 April 2020
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 11 (3-4) , 200-204
Abstract
Fine needle aspiration biopsy does not permit to distinguish between benign and malignant follicular thyroid lesions (category IV in the Bethesda Cytopathology System). Some reports have suggested an association between increased serum TSH levels and thyroid cancer, so the aim of this study was to investigate the association between TSH levels and malignancy in patients with follicular thyroid nodules. Therefore, we conducted a retrospective study of all subjects who underwent surgical treatment for Bethesda IV thyroid nodules in a single center (years 2012–2017). A total of 127 patients were analyzed, and malignancy was present in 38.6% of the patients. Using ROC analysis, the best TSH cut-off point to differentiate benign from malignant disease was 2.1 mU/l and the age cut-off with better sensitivity and specificity was 47 years. The proportion of subjects with TSH ≥ 2.1 mU/l was greater among subjects with cancer than in those with benign diseases (65.3 vs 44.9%, P = 0.029). The concurrence of both cut-off points (TSH ≥ 2.1 mU/l and age ≥ 47 years) showed a higher diagnostic accuracy than either of the two variables separately. Therefore, the present study supports an association between serum concentrations of TSH and risk of malignancy among subjects with Bethesda IV thyroid nodules. TSH levels could modify the diagnostic and therapeutic approach of patients with Bethesda IV nodules.Keywords
This publication has 32 references indexed in Scilit:
- The Bethesda System for Reporting Thyroid Cytopathology: A Meta-AnalysisActa Cytologica, 2012
- Predictors of Malignancy in Patients with Cytologically Suspicious Thyroid NodulesThyroid®, 2011
- L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patientsEndocrine-Related Cancer, 2010
- The utility of preoperative serum thyroid-stimulating hormone level for predicting malignant nodular thyroid diseaseThe American Journal of Surgery, 2010
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- The Bethesda System for Reporting Thyroid CytopathologyAmerican Journal of Clinical Pathology, 2009
- Epidemiology of thyroid nodulesBest Practice & Research Clinical Endocrinology & Metabolism, 2008
- Higher Serum Thyroid Stimulating Hormone Level in Thyroid Nodule Patients Is Associated with Greater Risks of Differentiated Thyroid Cancer and Advanced Tumor StageThe Journal of Clinical Endocrinology & Metabolism, 2008
- Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluationCancer, 2007
- Diagnostic Accuracy of Conventional Versus Sonography-Guided Fine-Needle Aspiration Biopsy of Thyroid NodulesThyroid®, 1998